biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by BearDownAZon May 31, 2017 2:55pm

131 Views

Post# 26307350

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Videos

JD wrote: "I'll stick with my contention that Transcend will never be tested, alone or with a dummy protein, in humans. The first introduction of Transcend into humans will be with a therapeutic load that has capability to efficaciously treat a disease, whether the disease turns out to be an LSD or a brain tumour."

JD, your statement above suggests that biOasis will go straight to Phase 1 trial and not Phase 0. I arrive at this interpretation because of the low, non-therapeutic doses used in Phase 0 trials. Are you suggesting that the first trial will be Phase 1?

If I understand correctly, the latest non-brokered private placement was for ~$4.1 million. Without trial details (Phase 0 or Phase 1, length of trial, number of patients, dose, frequency of dose, cost of manufacturing dose, cost of experimental assays/imaging, etc.) it is impossible to know if the $4.1 million is enough to proceed with a clinical study. If you are suggesting that Phase 1 will be the first trial and not Phase 0, then do you think that $4.1 million is enough?

Almost a year ago, RH replied to me via email saying "As for our oncology program we are in the process of preparing for a phase zero study, but the timing for that is predicated on material prep and patient availability."

It sure sounds like these Phase 0 plans have been in the works for some time now. Maybe they are changing plans to do a Phase 1 instead (assuming I understood JD's comment correctly). If so, is $4.1 million enough?

BearDownAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale